Skip to main content
IBRX $6.02 -8.37%
IBRX logo
IBRX · ImmunityBio, Inc.
Track IBRX — free
$6.02 -0.55 (-8.37%) At close · Nov 20 Q4 2025 earnings call transcript
Market Cap
$6.40B
Shares
1.06B
Volume · Nov 20 10.64M Avg daily vol (3M) 12.89M
All webcasts

Earnings call · FY2026 Q3

ImmunityBio, Inc. (IBRX) Q3 2026 Earnings Call

Concluded Nov 9, 2026
Nov 9, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $48.84M +52.3% YoY
Diluted EPS -$0.18
Gross margin · derived Q4 97.4% -2.0 pp YoY
Net income -$184.55M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year; FDA expanded ANKTIVA’s indication for BCG-unresponsive NMIBC, and Israel approval brought global approvals to 35.
10-Q report · filed Nov 9, 2026
ImmunityBio reported ANKTIVA’s October 14, 2026 FDA approval for BCG-unresponsive NMIBC with high-grade papillary-only tumors and Q3 2026 net product revenue of $48.7 million, up 53% year-over-year.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Product$48.74M +53.4% YoY
Product And Service Other$104,000 -63% YoY
Full-screen source Call document